Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 18/20 | 1.00 |
| ▸ | CLK1 | P49759 | 11/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | CLK2 | P49760 | 9/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 1.00 |
| ▸ | CLK3 | P49761 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675362 | 0.87 | CLK1 (0.82) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675243 | 0.85 | CLK1 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675329 | 0.81 | CLK4 (0.91) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675082 | 0.81 | CLK4 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675256 | 0.80 | CLK4 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675357 | 0.79 | CLK4 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675139 | 0.79 | CLK4 (0.74) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675335 | 0.79 | CLK4 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675309 | 0.79 | CLK4 (0.98) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL1675213 | 0.78 | CLK4 (1.00) | CLK4CLK1DYRK1ACLK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041655-A1 | QUINAZOLIN-4-AMINE DERIVATIVES; AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-04-07 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013026806-A1 | DYRK1 INHIBITORS AND USES THEREOF | EXONHIT SA (FR) | 2013-02-28 | — | — | WO | disclosed |
| WO-2011041655-A1 | QUINAZOLIN-4-AMINE DERIVATIVES; AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | CLK4 228/4885CLK1 83/4885DYRK1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.